Guangzhou University of Traditional Chinese Medicine Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2015
NCT02772016
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Haibo Zhang | Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine

Active Ingredients

Drugs in Phase 1 Trials (2)

collagen (1 trial)

mudan (1 trial)

Drugs in Other Trials (3)

anlotinib (1 trial)

irinotecan (Camptosar) (1 trial)

tislelizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thalassemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 5